Gapping down
In reaction to earnings/guidance:
- BLUE -14.6%, HBI -14.2%, PING -12.5%, FTDR -10.1%, LCI -8.2%, ELF -7.3%, ABUS -7.2%, STAA -6.4%, ZNGA -5.2%, TISI -5.1%, AXNX -4.9%, OSUR -4.6%, VAPO -4.6%, OESX -4.5%, BCRX -4%, OLN -3.7%, ING -3.4%, SVMK -3.3%, CNK -3.2%, IBP -3.1%, CF -2.5%, BABA -2.5%, ZTS -2.5%, LILA -2.4%, DYN -2.2%, XRAY -2.1%, NRG -2.1%, CTVA -2%, PXD -2%, KURA -2%, FOUR -1.9%, TRMB -1.8%, FROG -1.6%, HTHT -1.6%, NOMD -1.6%, BRX -1.3%, HFC -1.3%, NYT -1.1%, GDOT -1%, KRTX -1%, IGMS -1%, VMC -1%
Other news:
- APVO -10.3% (provided an update on preliminary data in its ongoing APVO436 Phase 1 clinical trial)
- STAA -6.4% (announces initial commercialization of EVO Viva presbyopia correcting lens)
- AVTR -4.6% (commences secondary offering)
- SFT -1.5% (filed a preliminary proxy statement and Schedule to which contemplates its intention to commence an offer to all holders of Shift's outstanding publicly-traded warrants to exchange shares of Shift common stock and cash for each warrant tendered)
Analyst comments:
- CORR -2.4% (downgraded to Sell from Hold at Stifel; tgt $1)
- VMC -1% (downgraded to Sector Perform from Outperform at RBC Capital Mkts)